Evidence
Front Public Health. 2024 Apr 4;12:1322460. doi: 10.3389/fpubh.2024.1322460. eCollection 2024.
ABSTRACT
Chronic liver disease is a leading cause of death in the US and is often preventable. Rising burden, cost, and fatality due to liver disease are driven by intensified alcohol use in the US population and the contributions of comorbid conditions. This mini-review focuses on the topic of liver health in the context of chronic, behavioral cofactors of disease, using research-based examples from the Brown University Center for Addiction and Disease Risk Exacerbation (CADRE). Our aim is to illustrate the current challenges and opportunities in clinical research addressing liver health in the context of behavioral and medical comorbidity and to highlight next steps in this crucial area of public health research and clinical care.
PMID:38638470 | PMC:PMC11024463 | DOI:10.3389/fpubh.2024.1322460
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Primary versus secondary psychosis in a patient with congenital liver disease
- Primary versus secondary psychosis in a patient with congenital liver disease
- New nomenclature for fatty liver disease
- Effects of Marine Natural Products on Liver Diseases
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder
- The role and mechanism of SUMO modification in liver disease
- Role of lactate and lactate metabolism in liver diseases (Review)
- Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inflammatory bowel disease in tertiary center
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives
- FGL1 and FGL2: emerging regulators of liver health and disease
- Recurrence of Primary Disease After Adult Liver Transplant - Risk Factors, Early Diagnosis, Management, and Prevention
- Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Association between nonalcoholic steatohepatitis and high serum ferritin levels in type 2 diabetes mellitus
- Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: A narrative review
- Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
- Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies
- Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
- Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD
- Risk of mortality among patients with alcohol-associated hepatitis in the US from 2007 to 2021
- Risk of mortality among patients with alcohol-associated hepatitis in the US from 2007 to 2021
- The roles and potential mechanisms of plant polysaccharides in liver diseases: a review
- The burden of non-alcoholic fatty liver disease in Australia: an analysis of Global Burden of Disease study from 1990 to 2019
- Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting
- The evolution of the liver transplant candidate
- Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
- Alcoholic Liver Disease in China: A Disease Influenced by Complex Social Factors That Should Not Be Neglected
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Relationship between Neutrophil-to-Lymphocyte Ratio and Liver Fibrosis in Nonalcoholic Fatty Liver Disease Among Adults in the United States: Data from the National Health and Nutrition Examination Survey 2017-2018
- The rs1862513 promoter variant of resistin gene influences susceptibility to nonalcoholic fatty liver disease
- AMPED study: Protocol for a randomized controlled trial of different doses of aerobic exercise training
- From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology
- Development of an alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell-derived liver organoids
- Development of an alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell-derived liver organoids
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- Attributable liver cancer deaths and disability-adjusted life years in China and worldwide: profiles and changing trends
- MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019
- Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019
- Alcohol-associated liver disease and public health policies
- LIVER HEALTH IS OVERLOOKED BY ALCOHOL DRINKERS IN BRAZIL
- Liver as a new target organ in Alzheimer's disease: insight from cholesterol metabolism and its role in amyloid-beta clearance
- Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD
- Hospital admissions for chronic liver diseases: a temporal study in the South Region of Brazil
- Alcohol, No Ordinary Commodity: policy implications for Canada
- Key role of interferon regulatory factor 1 (IRF-1) in regulating liver disease: progress and outlook
- Feeding the inflammasome to damage the liver
- Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- Quantitative assessment of self-management in patients with non-alcoholic fatty liver disease: An unmet clinical need
- Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
- Investigation of Markedly Elevated Liver Enzymes With Serendipitous Underlying Wilson's Disease With Chronic Alcohol Abuse
- The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)
- The Role of Extrahepatic Features on the Development and Management of Hepatocellular Carcinoma in Steatotic Liver Disease
- The Role of Extrahepatic Features on the Development and Management of Hepatocellular Carcinoma in Steatotic Liver Disease
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
Evidence Blueprint
Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Occult liver disease: a multinational perspective
- The gut-liver axis in fatty liver disease: role played by natural products
- Fatty liver disease's renaming impacts on drug clinical trials
- Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study
- Targeting Protein Phosphatases for the Treatment of Chronic Liver Disease
- Alcohol-Related liver disease: A global perspective
- Primary versus secondary psychosis in a patient with congenital liver disease
- Primary versus secondary psychosis in a patient with congenital liver disease
- COVID-19 in Individuals with Chronic Liver Diseases
- New nomenclature for fatty liver disease
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population-based study
- Effects of Marine Natural Products on Liver Diseases
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- The effect of liver disease on hepatic microenvironment and implications for immune therapy
- Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease
- Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder
- New Insights into Nutrition and Gut-Liver Axis: A Focus on Non-Alcoholic Fatty Liver Disease
- The role and mechanism of SUMO modification in liver disease
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Role of lactate and lactate metabolism in liver diseases (Review)
- Health status of patients with liver transplantation by alcohol-related disease vs another etiology: a cohort study
- Liver involvement in presence of heart disease and heart involvement in presence of liver disease: a conundrum
- Spatial genomics: mapping human steatotic liver disease
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- The double roles of T cell-mediated immune response in the progression of MASLD
- Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inflammatory bowel disease in tertiary center
- Therapeutic potential of oleanolic acid in liver diseases
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Research advances in serum chitinase-3-like protein 1 in liver fibrosis
- Epidemiological characteristics of inpatients with liver failure at the Beijing You'an Hospital from 2012 to 2021
- Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives
- FGL1 and FGL2: emerging regulators of liver health and disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Recurrence of Primary Disease After Adult Liver Transplant - Risk Factors, Early Diagnosis, Management, and Prevention
- Alcoholic liver disease - 2023
- The epidemiological characteristics of liver disease in hospitalized children: a 10-year single-center retrospective study
- Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Corrected and republished from: Metabolic associated liver disease
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Association between nonalcoholic steatohepatitis and high serum ferritin levels in type 2 diabetes mellitus
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- Preventive hepatology at AIIMS Rishikesh: Delivering comprehensive and integrated care for liver diseases in Northern state of India
- Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: A narrative review
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- The significance of omega-3 fatty acids in the treatment of non-alcoholic fatty liver disease
- Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
- Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
- Inflammatory liver diseases and susceptibility to sepsis
- Liver cirrhosis in a patient with alcohol dependence and autoimmune hepatitis
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices